Compare BMRA & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | ICU |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | BMRA | ICU |
|---|---|---|
| Price | $2.15 | $2.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.6K | ★ 119.4K |
| Earning Date | 01-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,457,000.00 | $881,000.00 |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $2.11 | $2.20 |
| 52 Week High | $8.80 | $25.70 |
| Indicator | BMRA | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 56.17 |
| Support Level | $2.14 | $2.31 |
| Resistance Level | $2.33 | $2.74 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 18.09 | 21.57 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.